Novo Nordisk has said that it is committed to continuing to supply porcine insulin in those countries where demand still exists into the next millennium, but will not supply it in cartridges for use in pen injection devices, for economic reasons. The comments came in response to campaigns from the British Diabetic Association.
The calls to maintain supply of animal insulin stem from reports that some patients lose their warning signs of hypoglycemia when switching to the recombinant human version.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze